FDA regulation, lengthy time to market and high cost of development delay the release of new Class III medical devices and Biologic therapies. Many indications exist in which Class II biomaterial therapies could provide improved outcomes while possessing a fast route to market and significantly reduced cost compared to Class III devices and Biologics. Rosivo aims to develop biomaterial therapies to treat these indications.Rosivo, located at the BioInnovations Gateway in South Salt Lake, is a development stage medical device company with award-winning, patented technologies for producing refined biological implants.